CellCura ASA ("CellCura", "the Company") is proud to announce that the Company has been awarded a research grant of NOK 6 million from the Research Council of Norway ("the Research Council") to support its research project "Computer Aided Sperm Analysis and Recognition" (CASPAR).  The grant is awarded through the Research Council's programme for "User-driven Research based Innovation" ("BIA"). BIA aims at supporting Norwegian businesses' ability to develop and commercialise user-driven innovation of the highest international standards.

"We are very proud of having passed the mark on this occasion", comments CellCura's project manager, Bent Nordbø. "We know that the competition for BIA research funds is fierce and that grants are only awarded to the very best projects. This grant serves as yet another recognition of the visionary research developments within cell technologies driven forward by CellCura".

The project is aimed at developing new methods for sperm analysis that will enable clinicians to identify genetically and morphologically normal sperm cells through the use of non-destructive technology. Such technology will be of great importance in the treatment of involuntarily infertile people, especially in instances where male infertility is detected. CellCura has on the CASPAR project teamed up with leading expert centres within ART and technological innovation.

Characteristic for all companies receiving grants from the BIA programme is the ability and motivation to deliver high-quality R&D projects with good business and socio-economic potential.

For further information please contact CellCura's Chief Operating Officer Bent Nordbø (+47 901 89 517).

Oslo, 29 January 2014

CellCura ASA
Tore Viana-Rønningen
Chief Executive Officer
+47 911 08 693
tvr@cellcura.com

CellCura ASA is dedicated to the development and sales of cell technologies for use in assisted reproductive technology (ART) and stem cell research worldwide, representing improved safety and efficiency compared to traditional technology. CellCura is listed on the Oslo Axess market at the Oslo Stock Exchange (ticker: CELL). www.cellcura.com

This information is subject of the disclosure requirements acc. Verdipapirhandelloven §5-12 (the Norwegian Securities Trading Act).

distributed by